Global Microbiome Therapeutics Market Report and Forecast 2023-2031

Global Microbiome Therapeutics Market Report and Forecast 2023-2031


Global Microbiome Therapeutics Market Outlook:


The global microbiome therapeutics market value was USD 215.6 million in 2022, driven by the increasing recognition of the role of the human microbiome in health and disease across the globe. The market size is anticipated to grow at a CAGR of 40.2% during the forecast period of 2023-2031 to achieve a value of USD 3462.2 million by 2031.

Introduction

Microbiome therapeutics is a rapidly emerging field in healthcare that focuses on harnessing the potential of the human microbiome to prevent, diagnose, and treat various diseases. The human microbiome refers to the vast community of microorganisms, including bacteria, viruses, fungi, and other microbes, that reside within the human body, particularly in the gastrointestinal tract.

The microbiome plays a crucial role in maintaining overall health and well-being. It is involved in various physiological processes, such as digestion, immune function, metabolism, and even mental health. Imbalances or disruptions in the microbiome composition, known as dysbiosis, have been associated with the development of numerous diseases, including gastrointestinal disorders, metabolic disorders, autoimmune conditions, and even neurological conditions.

Microbiome therapeutics aims to manipulate and restore the balance of the microbiome through various approaches, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and targeted antimicrobial therapies. Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. Prebiotics are substances that selectively promote the growth and activity of beneficial bacteria in the gut. FMT involves transferring fecal material from a healthy donor to a recipient to restore a healthy microbiome.

Key Trends in the Microbiome Therapeutics Market


Some key trends involved in the microbiome therapeutics market are as follows:

Increasing Research and Development: There is a surge in research and development activities focused on understanding the role of the microbiome in health and disease. This includes studying the composition, functionality, and interactions of microbial communities in various body sites. The growing body of scientific evidence is driving the development of new microbiome-based interventions.
Advancements in Sequencing Technologies: Next-generation sequencing technologies have revolutionized the study of the microbiome by enabling comprehensive profiling of microbial communities. The ability to sequence and analyze large amounts of genetic data has facilitated the identification of specific microbial signatures associated with different diseases and health conditions. These advancements are leading to the development of more targeted and personalized microbiome therapeutics.
Expansion of Clinical Applications: Microbiome therapeutics initially focused on gastrointestinal disorders, such as Clostridium difficile infection. However, there is a growing recognition that dysbiosis of the microbiome can impact various aspects of health beyond the gut. As a result, there is an increasing exploration of microbiome-based interventions for conditions such as metabolic disorders, autoimmune diseases, mental health disorders, and even cancer.
Development of Novel Therapies: Researchers and biotechnology companies are developing innovative approaches to modulate the microbiome. This includes the use of genetically engineered microbes or microbial consortia with specific functions, targeted delivery systems, and engineered probiotics. These advancements aim to enhance the therapeutic efficacy and specificity of microbiome-based interventions.

Microbiome Therapeutics Market Segmentations


Market Breakup by Type

Faecal Microbial Transplant
Microbiome Drugs
Market Breakup by Applications

Inflammatory Bowel Disease
Diabetes
Crohn’s Disease
Clostridium Difficile Infection
Others
Market Breakup by End User

Hospitals
Homecare
Ambulatory Surgical Centers
Others
Market Breakup by Region

North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Italy
Others
Asia Pacific
China
Japan
India
ASEAN
Australia
Others
Latin America
Brazil
Argentina
Mexico
Others
Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others

Microbiome Therapeutics Market Scenario


The market for microbiome therapeutics is witnessing significant growth and is expected to have a profound impact on the healthcare industry. The human microbiome, comprising trillions of microorganisms that reside in and on our bodies, has been recognized as a key determinant of health and disease. Microbiome therapeutics aim to modulate the composition and function of these microbial communities to restore and maintain health.

The increasing understanding of the role of the microbiome in various diseases, coupled with advancements in sequencing technologies and bioinformatics, has fueled the development of microbiome-based interventions. The market is witnessing a surge in research and development activities, with a focus on identifying specific microbial signatures associated with different diseases and developing targeted therapies.

One of the major drivers of the microbiome therapeutics market is the increasing recognition of the role of the human microbiome in health and disease. The understanding that the composition and function of microbial communities in our bodies can influence various aspects of our well-being has fueled the demand for microbiome-based interventions. This growing awareness among healthcare professionals, researchers, and patients has led to increased investments in research and development and a surge in clinical trials exploring the potential of microbiome therapeutics.

Microbiome Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Seres Therapeutics
Rebiotix, Inc.
Enterome Bioscience
MaaT Pharma
Vedanta Biosciences, Inc.
AOBiome LLC


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Microbiome Therapeutics Market Overview
3.1 Global Microbiome Therapeutics Market Historical Value (2016-2022)
3.2 Global Microbiome Therapeutics Market Forecast Value (2023-2031)
4 Global Microbiome Therapeutics Market Landscape
4.1 Global Microbiome Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Microbiome Therapeutics Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
4.2.3 Analysis by End User
5 Global Microbiome Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Microbiome Therapeutics Market Segmentation
6.1 Global Microbiome Therapeutics Market by Type
6.1.1 Market Overview
6.1.2 Faecal Microbial Transplant
6.1.3 Microbiome Drugs
6.2 Global Microbiome Therapeutics Market by Applications
6.2.1 Market Overview
6.2.2 Inflammatory Bowel Disease
6.2.3 Diabetes
6.2.4 Crohn’s Disease
6.2.5 Clostridium Difficile Infection
6.2.6 Others
6.3 Global Microbiome Therapeutics Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Homecare
6.3.4 Ambulatory Surgical Centers
6.3.5 Others
6.4 Global Microbiome Therapeutics Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Microbiome Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Microbiome Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Microbiome Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Microbiome Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Microbiome Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Seres Therapeutics
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Rebiotix, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Enterome Bioscience
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 MaaT Pharma
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Vedanta Biosciences, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 AOBiome LLC
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
18 Global Microbiome Therapeutics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings